Theralase Technologies Inc.
TLTFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -3.4% | -6% | 45.9% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $1 | $1 | $1 | $0 |
| % Margin | 53.6% | 52.5% | 55.2% | 39.7% |
| R&D Expenses | $3 | $3 | $4 | $3 |
| G&A Expenses | $2 | $2 | $1 | $2 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $5 | $6 | $5 |
| Operating Income | -$4 | -$5 | -$5 | -$5 |
| % Margin | -415% | -429.2% | -459.5% | -581.8% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$4 | -$5 | -$5 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$5 | -$5 | -$4 |
| % Margin | -411.8% | -427.1% | -459.8% | -565.1% |
| EPS | -0.018 | -0.021 | -0.025 | -0.022 |
| % Growth | 14.9% | 17.5% | -16.7% | – |
| EPS Diluted | -0.018 | -0.021 | -0.025 | -0.022 |
| Weighted Avg Shares Out | 240 | 220 | 208 | 204 |
| Weighted Avg Shares Out Dil | 240 | 220 | 208 | 204 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$5 | -$4 |
| % Margin | -383.2% | -397.5% | -430.4% | -529% |